鼻窦手术范围与生物制剂治疗2型优势CRS的疾病控制相关
这项横断面研究纳入159例接受生物制剂≥6个月的难治性2型优势CRSwNP患者,所有患者均曾接受鼻窦手术。结果显示49.1%患者达到疾病控制,扩展手术(Draf III/IIc)与疾病控制显著相关(OR 110.2),而生物制剂类型间无显著差异。
要点
- 扩展鼻窦手术(Draf III/IIc)与生物制剂治疗CRSwNP的疾病控制显著相关
- 生物制剂类型(抗IL-4αR vs 抗IL-5/5R)与疾病控制无显著关联
- Draf IIa/I组疾病控制率仅8.7%/0%,远低于Draf III/IIc组
核心结论
- 在生物制剂治疗的难治性2型优势CRSwNP患者中,扩展鼻窦手术(Draf III+IIc)与疾病控制独立相关,而生物制剂类型无显著关联。
研究设计与样本
- 横断面研究,纳入159例接受生物制剂≥6个月的CRSwNP患者(年龄50.9±12.8岁,45.3%女性),所有患者均曾接受鼻窦手术(蝶筛切除术并扩展至Draf I、IIa、IIb、IIc或III)。
主要发现
- 49.1%患者达到疾病控制。
- 疾病控制率随手术扩展程度增加:Draf III 60.8% [49.7%-70.8%],Draf IIc 68.3% [53.0%-80.4%],Draf IIa 8.7% [2.4%-26.8%],Draf I 0% [0.0%-19.4%];p < 0.001。
- 生物制剂类型间疾病控制率无显著差异:抗IL-4αR 63.3% [45.5%-78.1%] vs 抗IL-5/5R 45.7% [37.3%-54.3%];p = 0.083。
- 回归分析显示扩展手术(Draf III/IIc vs Draf IIa/I)与疾病控制相关(OR: 110.2 [12.7-14,682.5]),生物制剂类型无显著关联(抗IL-4αR vs 抗IL-5/5R OR: 2.2 [0.7-7.2])。
- 15.1%初始接受抗IL-5/5R治疗的患者已发生类别转换。
关键数值与推荐
- 疾病控制定义为SNOT-22 ≤ 30、内镜改良Lund-Mackay ≤ 4且6个月内无挽救治疗。
临床怎么用
- 对于计划接受生物制剂治疗的难治性2型优势CRSwNP患者,应考虑充分的扩展性鼻窦手术(如Draf III或IIc)以提高疾病控制概率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP. METHODS: A cross-sectional study was performed on patients with CRSwNP treated with biologics for ≥ 6 months at a tertiary center. All patients had undergone prior sinus surgery, which included a sphenoethmoidectomy and then extension via Draf I, IIa, IIb, IIc, or III. Disease control was defined as having a SNOT-22 ≤ 30, endoscopic modified Lund-Mackay ≤ 4, and the absence of rescue therapy within 6 months. Comparisons were made across surgical and biologic groups, and logistic regression was used to identify factors associated with disease control. RESULTS: A total of 159 patients were assessed (age 50.9 ± 12.8 years, 45.3% female). Disease control was achieved in 49.1% of patients. Disease control was greater with extended surgery (Draf III 60.8% [49.7%-70.8%] vs. Draf IIc 68.3% [53.0%-80.4%] vs. Draf IIa 8.7% [2.4%-26.8%] vs. Draf I 0% [0.0%-19.4%]; p < 0.001). The control was similar across biologic types (anti-IL-4αR 63.3% [45.5%-78.1%] vs. anti-IL-5/5R 45.7% [37.3%-54.3%]; p = 0.083). On regression, extended surgery (Draf III + IIc) was associated with disease control (Draf III/IIc vs. Draf IIa/I OR: 110.2 [12.7-14,682.5]) but not biologic type (anti-IL-4αR vs. anti-IL-5/5R OR: 2.2 [0.7-7.2]). However, class switching had already occurred in 15.1% of patients initially treated with anti-IL-5/5R. CONCLUSIONS: Disease control was greatest in CRSwNP patients who had both extended sinus surgery and optimized biologic treatment.
引用
- Campion NJ, Sacks PL, Png LH, et al. Extent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS. Int Forum Allergy Rhinol. 2026. PMID: 41961456. doi:10.1002/alr.70166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。